RECRUITINGINTERVENTIONAL
Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can)
Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada -EMMA-Can
About This Trial
EMMA-Can is a prospective cohort study to assess the safety and effectiveness of MMA-embolization for the treatment of CSDH. Hypothesis- EMMA reduces the recurrence rate of CSDH with or without concomitant surgical evacuation.
Who May Be Eligible (Plain English)
Who May Qualify:
\- All patients with subdural hematoma coming to the emergency room or to neurosurgical outpatient clinic.
Who Should NOT Join This Trial:
- If willing to sign a consent form cannot be obtained from the patient or their substitute decision maker.
- Known allergy to liquid embolic agent
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
\- All patients with subdural hematoma coming to the emergency room or to neurosurgical outpatient clinic.
Exclusion Criteria:
* If informed consent cannot be obtained from the patient or their substitute decision maker.
* Known allergy to liquid embolic agent
Treatments Being Tested
PROCEDURE
Embolization of the middle meningeal artery
embolization of the middle meningeal artery with an embolic agent (Microparticles, liquid embolic agents, SwiftPAC coils or others).
Locations (1)
Health Sciences centre
Winnipeg MB, Manitoba, Canada